Innate Pharma (IPHYF) Total Current Liabilities (2017 - 2025)

Innate Pharma's Total Current Liabilities history spans 9 years, with the latest figure at $42.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 21.04% year-over-year to $42.7 million; the TTM value through Dec 2025 reached $42.7 million, up 21.04%, while the annual FY2025 figure was $42.7 million, 19.51% up from the prior year.
  • Total Current Liabilities reached $42.7 million in Q4 2025 per IPHYF's latest filing, up from $35.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $91.4 million in Q4 2021 to a low of $35.2 million in Q4 2024.
  • Average Total Current Liabilities over 5 years is $50.8 million, with a median of $42.6 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 68.5% in 2021, then crashed 53.85% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $91.4 million in 2021, then plummeted by 53.85% to $42.2 million in 2022, then rose by 1.12% to $42.6 million in 2023, then decreased by 17.36% to $35.2 million in 2024, then increased by 21.04% to $42.7 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Total Current Liabilities are $42.7 million (Q4 2025), $35.2 million (Q4 2024), and $42.6 million (Q4 2023).